Tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer.

Carmen CriscitielloA VingianiP MaisonneuveG VialeG VialeG Curigliano

Published in: Breast cancer research and treatment (2020)

High TILs in ER+/HER2- BC are significantly associated with clinico-pathological features of dismal outcome. TIL prognostic value seems different in patients treated with or without chemotherapy. Our findings suggest that the high-risk subgroup might be more immunogenic, thus deserving the exploration of immunotherapy approaches.

Keyphrases

endoplasmic reticulum
estrogen receptor
breast cancer cells
peripheral blood
locally advanced
squamous cell carcinoma
radiation therapy
open label
chemotherapy induced